Proliferative Diabetic Retinopathy (PDR) Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Long-Term Projected Growth Rate for the Proliferative Diabetic Retinopathy (PDR) Market, and What Are the Key Drivers?
The market size for proliferative diabetic retinopathy (PDR) has seen swift expansion in past few years. The market value is projected to rise from $2.42 billion in 2024 to $2.7 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%. The surge in growth during the historic period can be credited to an increase in cases of diabetes, lifestyle transformations, consumption of unhealthy food, government actions, and escalating instances of vision loss due to diabetes.
The market size for proliferative diabetic retinopathy (PDR) is projected to experience swift expansion in the forthcoming years, reaching $4.02 billion in 2029 with a compound annual growth rate (CAGR) of 10.5%. The projected growth during this period can be credited to factors such as an aging population, increased public understanding and education related to diabetes, investment in research and development, as well as a surge in demand for combination therapies. Key trends anticipated during this forecast period include advancements in diagnostic technologies, revolutionary treatments options, the use of artificial intelligence (AI) for early diagnosis, progress in gene therapy, and advanced retinal imaging.
What Are the Primary Drivers Supporting the Growth of the Proliferative Diabetic Retinopathy (PDR) Market?
The growth of the proliferative diabetic retinopathy (PDR) market is anticipated to be propelled by the increasing instances of diabetes. Diabetes is a persistent medical disorder where the blood contains excessive glucose (sugar) levels. Diabetes is the primary cause of the proliferative diabetic retinopathy disease, for which there are several treatment methods available to prevent further damage to the retina and preserve vision. For instance, the National Health Service (NHS), a UK-based government department, revealed in June 2024, that there was a substantial rise amongst those under 40, from 173,166 in 2022 to 216,440 in 2023. The sudden increase points to a worrying trend in this age group and suggests a quick surge in diabetes incidence among younger populations. Thus, the upsurge in diabetes cases is fueling the growth of the proliferative diabetic retinopathy (PDR) market. The proliferative diabetic retinopathy (PDR) market’s potential growth is likely to be influenced by the increasing occurrence of obesity. Obesity is a multifaceted, long-term disease with several roots leading to surplus body fat and often, poor health. It is connected with insulin resistance, continuous minor inflammation, and increased oxidative stress, which can harm the retinal microvasculature and contribute to proliferative diabetic retinopathy’s onset. The Trust for America’s Health, a non-profit organization headquartered in the US, stated in their 2022 report that obesity rates in the US keep rising, with four out of ten American adults being obese. This is a marked increase from the previous year, as 19 states now have adult obesity rates over 35%, a climb from 16 states last year. Consequently, the escalating occurrence of obesity is catalyzing the expansion of the proliferative diabetic retinopathy (PDR) market.
Request Your Free Proliferative Diabetic Retinopathy (PDR) Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp
Which Companies Are Leading the Charge in Expanding the Proliferative Diabetic Retinopathy (PDR) Market?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are:
• Pfizer Inc._x000D_
• Johnson and Johnson Limited_x000D_
• F. Hoffmann-La Roche Ltd._x000D_
• Merck and Co. Inc._x000D_
• AbbVie Inc._x000D_
What New Trends Are Reshaping the Proliferative Diabetic Retinopathy (PDR) Market and Its Opportunities?
Prominent firms in the proliferative diabetic retinopathy market are consistently devoted to the innovation of new therapies in an effort to augment the efficacy of treatment, lessen the treatment burden, and enhance patient results. For instance, in June 2022, Biogen, a biotech corporation based in the US, and Samsung Bioepis, a South Korean biotech firm, launched Byooviz (ranibizumab-nuna), the inaugural ophthalmology biosimilar in the US. These commodities are utilized for the treatment of patients suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.
Pre-order Your Report for Quick and Easy Delivery!
Which Key Market Segments Comprise the Proliferative Diabetic Retinopathy (PDR) Market and Drive Its Revenue Growth?
The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –
1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy
2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations
3) By Application: Hospitals, Clinics, Other Applications
Subsegments:
1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy
What Are the Top Regions Fueling Growth in the Proliferative Diabetic Retinopathy (PDR) Market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Defines the Scope of the Proliferative Diabetic Retinopathy (PDR) Market?
Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management.
Browse Through More Similar Reports By The Business Research Company:
Pet Diabetes Care Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-devices-global-market-report
Insulin Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report
Smart Insulin Pens Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
